

1646

PATENT / LU Atty. Docket No.: 0402-UTL-5

Confirmation No.: 7370

Examiner: LI, RUIXIANG

TC/A.U.:

ED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.:

10/518,128

Inventors:

GEDULIN et al.

Filed:

June 13, 2003

Title: Prevention and/or Treatment of Inflammatory

Bowel Disease Using PYY or Agonists Thereof

TRANSMITTAL

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The following documents are enclosed herewith for your review and consideration:

- Information Disclosure Statement;
- PTO/SB/08 (31 Sheets);
- Copies of 329 References; and
- Return Receipt Postcard

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: 17 mar 2006

Susan J. Myers Fitch, Ph.D.

Registration No. 55,477

AMYLIN PHARMACEUTICALS, INC.

9360 Town Centre Drive

San Diego, CA 92121

Telephone: 858.552.2200

Facsimile: 858.552.1936

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8a

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient First Class postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Mar 2006

Date of Deposit

7an Name of Person Mailing Paper



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.:

10/518,128

Inventors:

GEDULIN et al.

Filed:

June 13, 2003

Title: Prevention and/or Treatment of Inflammatory

Bowel Disease Using PYY or Agonists Thereof

Confirmation No.: 7370

TC/A.U.:

1646

Examiner: LI, RUIXIANG

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

In compliance with 37 C.F.R. §1.56, the patent documents and references listed on the attached Form PTO/SB/08 are being submitted herewith for consideration by the Examiner. In accordance with 37 C.F.R. 1.98, a copy of each of the listed items, other than U.S. Patents and U.S. Patent Application Publications, is included herewith.

The references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. 1.97(b) in that Applicants believe that it is being filed before the mailing date of the first Office Action on the merits. Accordingly, neither a statement nor a fee under 37 C.F.R. 1.97(c) is required. If Applicants are mistaken, and the mailing date of the first Office Action on the merits precedes the filing of this Supplemental Information Disclosure Statement, Applicants authorize that the fee due under 37 C.F.R. 1.17(p) be charged to Deposit Account No 010535. Additionally, the

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8a

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient First Class postage in an envelope addressed to the Commissioner for Patents, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

2006 War

Date of Deposit

Signature of Person Mailing Paper

Name of Person Mailing Paper

USSN 10/518,128

Atty. Docket: 0402-UTL-5

Page 2

Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully Submitted

AMYLIN PHARMACEUTICALS, INC.

Dated: 17 mar 2006

Susan J. Myers Fitch, Ph.D. /Registration No. 55,477

AMYLIN PHARMACEUTICALS, INC.

9360 Towne Centre Drive San Diego, CA 92121

Telephone: (858) 552-2200 Facsimile: (858) 552-1936

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE red to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of

Sheet 1

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 31

Complete if Known				
Application Number	10/518,128			
Filing Date	June 13, 2003			
First Named Inventor	Bronislava Gedulin			
Art Unit	1646			
Examiner Name	LI, RUIXIANG			
Attorney Docket Number	0402-UTL-5			

	-		U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 4,683,195	7-28-1987	Mullis et al.	3
		^{US-} 4,683,202	7-28-1987	Mullis	
		US- 4,839,343	6-13-1989	Waeber et al.	
		^{US-} 4,891,357	01-02-1990	Kala	
		^{US-} 4,892,538	01-09-1990	Aebisher et al.	
		^{US-} 5,459,039	10-17-1995	Modrich et al.	
		^{US-} 5,498,531	03-12-1996	Jarrell	
		^{US-} 5,574,010	11-12-1996	McFadden	
		^{US-} 5,696,093	12-09-1997	Tseng	
		^{US-} 5,824,784	10-20-1998	Kinstler et al.	
		^{US-} 5,824,778	10-20-1998	Ishikawa et al.	
		^{US-} 5,912,227	06-15-1999	Croom, Jr. et al.	
		^{US-} 5,939,462	08-17-1999	Connell et al.	
		^{US-} 5,968,819	10-19-1999	Gerald et al.	
		^{US-} 5,980,945	11-9-1999	Ruiz	•
		^{US-} 6,013,622	01-11-2000	Bruno et al.	
		^{US-} 6,315,203	11-13-2001	lkeda et al.	
		^{US-} 6,355,478	03-12-2002	Baez et al.	
<i>-</i>		^{US-} 6,391,343	05-21-2002	Yen	

FOREIGN PATENT DOCUMENTS						
Examiner Cite Initials* No.1	Cite No.1	ite Foreign Patent Document Publication		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		Or Relevant Figures Appear	Τ°
		EP 0 992 239 B1	03-12-2003	Banyu Pharma Co Ltd		
		WO 83/04053	11-24-1983	Applied Molecular Genetic		
	1.	WO 89/01967	03-09-1989	Brown University Research		
		WO 90/02580	03-22-1990	Brown University Research		
		WO 90/15637	12-27-1990	Brown University Research		
		WO 91/10425	07-25-1991	Brown University Research		厂

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 31

Complete if Known				
Application Number	10/518,128			
Filing Date	June 13, 2003			
First Named Inventor	Bronislava Gedulin			
Art Unit	1646			
Examiner Name	LI, RUIXIANG			
Attomey Docket Number	0402-UTL-5			

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear	
***		^{US-} 6,420,532	07-16-2002	Gerald et al.		
		^{US-} 6,558,708 B1	05-06-2003	Lin		
		^{US-} 6,734,166	05-11-2004	Croom, Jr. et al.		
		^{US-} 2002/0094346-A1	07-18-2002	Lin		
		^{US-} 2004/0228846	11-18-2004	Pang et al.		
		US-	·			
		US-				
		US-				
		US-	•		************	
		US-			***************************************	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-			<u> </u>	
		US-				
		US-				
-		US-				

			<u>GN PATENT DOCL</u>	JMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		WO 91/10470	07-25-1991	Brown University Research		
		WO 94/16101	07-21-1994	Hubert Koster		
		WO 99/07404	02-18-1999	Amylin Pharmaceuticals, I		
		WO 99/15516	04-01-1999	Banyu Pharma Co Ltd		
		WO 99/25727	05-27-1999	Amylin Pharmaceuticals, I		
		WO 99/25728	05-27-1999	Amylin Pharmaceuticals, I		

Examiner	Date	
Signature	Considered	
	 1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 31

Under the Paperworl	k Reduction Act of 1995, no persons are require	ed to respond to a collection of informa	ition unless it contains a valid OMB cont	rol number		
Substitute for form	1449/PTO	Complete if Known				
		Application Number	10/518,128			
INFORM	ATION DISCLOSURE	Filing Date	June 13, 2003			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor	Bronislava Gedulin			
		Art Unit	1646			
(Use a	as many sheets as necessary)	Examiner Name	LI, RUIXIANG	-		
neet 3	of 31	Attorney Docket Number	0402-UTL-5			

Examiner	Cite	Document Number	U. S. PATENT D	Name of Patentee or	Pages, Columns, Lines, Where
nitials*	Cite No.1		MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan
		Number-Kind Code ^{2 (# known)}			Figures Appear
		US-			
		US-			
		US-			
_		US-			
		US-			
		US-		4	
		US-			
		US-	1	****	
		US-			
		US-			
		US-			***************************************
		US-			
		US-		, ,,,	
-		US-			
		US-	·		

			N PATENT DOCL	IMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		WO 00/47219	08-17-2000	Ontogeny, Inc.		
		WO 00/68197	11-16-2000	Ortho McNeil Pharm		
		WO 01/62737	08-30-2001	Ortho McNeil Pharm		
		WO 01/76631	10-18-2001	Cedars Sinai Medical		
		WO 03/026591 A2	04-03-2003	Imperial College		
		WO 03/057235	05-17-2003	Imperial College		

Examiner		Date	
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 4

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 31

Cor	nplete if Known	
Application Number	10/518,128	
Filing Date	June 13, 2003	
First Named Inventor	Bronislava Gedulin	
Art Unit	1646	
Examiner Name	LI, RUIXIANG	
Attorney Docket Number	0402-LITL-5	

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code ^{2 (f known)}			Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
•		US-				
		US-				
		US-				
		US-				
		US-		···		
		US-				
		US-				
· · ·		US-				
		US-				
		US-				

		FOREIG	N PATENT DOCL	JMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	76
		WO 03/105763	12-24-2003	Amylin Pharmaceuticals, I		
	<u> </u>					

Examiner	Di	ate	
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO				Complete if Known
Cabalita	10.101.101.11.1.101.1.10			Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	ote se n	acassani)	Art Unit	1646
	(Ose as many sne	-	ecessary)	Examiner Name	LI, RUIXIANG
Sheet	5	of	31	Attorney Docket Number	0402-UTL-5

<u>-</u>		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Adrian, T.E., et al., Gastroenterology 89, 1070-1077 (1985)	
		Adrian, T.E., et al., Digestion 21, 214-218 (1981)	
,		Ahren, B. et al., Eur J Endocrinol 134, 362-365 (1996)	
		Allen, J.M., et al., Digestion 30, 255-262 (1984)	
		Ando, R., et al., Eur J Pharmacol 427, 53-59 (2001)	
		Andres, C.J., et al., Bioorg Med Chem Lett 13, 2883-2885 (2003)	
		Aponte, G.W., et al., FASEB J 3, 1949-55 (1989)	
		Aponte, G.W. Peptides 23, 367-376 (2002)	
		Asakawa, A., et al., Peptides 20, 1445-1448 (1999)	
	1	Bader, R., et al., Biochemistry 41, 8031-8042 (2002)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI

	ite for form 1449/PTO				Complete if Known
0000				Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	ote se n	acossan)	Art Unit	1646
	1036 as many sno		ecessary)	Examiner Name	LI, RUIXIANG
Sheet	6	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Balasubramaniam, A., et al., Peptides 14, 1011-1016 (1993)	
		Balasubramaniam, A., et al., Int J Pept Protein Res 29, 78-83 (1987)	
- · · · · · · · · · · · · · · · · · · ·		Balasubramaniam, A., et al., Pept Res 1, 32-35 (1988)	
		Balasubramaniam, A., et al., Peptides 23, 1485-1490 (2002)	
		Balasubramaniam, A., et al., J Med Chem 43, 3420-3427 (2000)	
		Balasubramaniam, A.A. Peptides 18, 445-457 (1997)	
		Barany, F. Proc Natl Acad Sci U S A 88, 189-193 (1991)	
		Bartlett PA, et al., Bioorg Chem.14:356-377 (1986)	
		Batterham, R.L., et al., N Engl J Med 349, 941-948 (2003)	
		Batterham, R.L., et al., Nature 418, 650-654 (2002)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e for form 1449/PTO				Complete if Known
Cassina				Application Number	10/518,128
INFO	DRMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	ets as n	ecessary)	Art Unit	1646
	Tool as many one	0.0 00		Examiner Name	LI, RUIXIANG
Sheet	7	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Beck, A., et al., FEBS Lett 244, 119-122 (1989)	
		Beck-Sickinger, A.G., et al., J Recept Res 13, 215-228 (1993)	
		Beltowski, J. et al., Pol J Pharmacol 56, 5-27 (2004)	
i.,		Berge, S.M., et al., J Pharm Sci 66, 1-19 (1977)	
		Berglund, M.M., et al., Exp Biol Med (Maywood) 228, 217-244 (2003)	
		Bertrand, G., et al., Pancreas 7, 595-600 (1992)	
		Birdsall, N.J.M. et al., Trends Pharmacol Sci 4, 459-463 (1983)	
		Bischoff, A. et al., Trends Pharmacol Sci 20, 104-106 (1999)	
		Bonaz, B., et al., Neurosci Lett 163, 77-80 (1993)	
		Bottcher, G., et al., Pancreas 4, 282-288 (1989)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

	ite for form 1449/PTO			e required to respond to a conection	Complete if Known			
				Application Number	10/518,128			
INF	ORMATION	I DIS	CLOSURE	Filing Date	June 13, 2003			
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin			
	(Use as many she	aate ae n	arassanı)	Art Unit	1646			
	(Use as many sine	2013 a3 11	ecessary	Examiner Name	LI, RUIXIANG			
Sheet	8	of	31	Attorney Docket Number	0402-UTL-5			

	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	Boublik, J.H., et al., J Med Chem 32, 597-601 (1989)	
	Bourguet E, et al., Bioorg Med Chem Lett.13:1561-1564 (2003)	
	Bousquet-Melou, A., et al., J Lipid Res 36, 451-461 (1995)	
	Brown, K.K., et al., Diabetes 48, 1415-1424 (1999)	
	Cabrele, C. et al., J Pept Sci 6, 97-122 (2000)	
	Cabrele, C., et al., J Biol Chem 275, 36043-36048 (2000)	
	Cabrele, C., et al., Biochemistry 41, 8043-8049 (2002)	
	Cabrele, C., et al., Peptides 22, 365-378 (2001)	
	Camilleri, M., et al., Gut 22, 14-18 (1981)	
	Campfield, L.A., et al., Science 269, 546-549 (1995)	
	Cite No.1	Cite No.¹ Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Boublik, J.H., et al., J Med Chem 32, 597-601 (1989) Bourguet E, et al., Bioorg Med Chem Lett.13:1561-1564 (2003) Bousquet-Melou, A., et al., J Lipid Res 36, 451-461 (1995) Brown, K.K., et al., Diabetes 48, 1415-1424 (1999) Cabrele, C. et al., J Pept Sci 6, 97-122 (2000) Cabrele, C., et al., J Biol Chem 275, 36043-36048 (2000) Cabrele, C., et al., Biochemistry 41, 8043-8049 (2002) Cabrele, C., et al., Peptides 22, 365-378 (2001) Camilleri, M., et al., Gut 22, 14-18 (1981)

Examiner	-	Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO				Complete if Known
Cabalita				Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	ate se n	acassand	Art Unit	1646
	(OSB as many sne	ets as II	ecessary)	Examiner Name	LI, RUIXIANG
Sheet	9	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Chance WT, et al., Life Sci.58:1785-1794 (1996)	
		Chen, C.H. et al., Am J Physiol 269, R787-R792 (1995)	
		Chen, C.H., et al., Regul Pept 61, 95-98 (1996)	
		Chen, C.H., et al., Neurogastroenterol Motil 9, 109-116 (1997)	
		Chen, M.H., et al., Sensitive Gastroenterology 87, 1332-1338 (1984)	
		Chen, Z., et al., FEBS Lett 492, 119-122 (2001)	
		Clark, J.T., et al., Endocrinology 115, 427-429 (1984)	
		Clark, J.T., et al., Regul Pept 17, 31-39 (1987)	
		Conlon, J.M. Peptides 23, 269-278 (2002)	
		Cook, D.L. et al., Nature 311, 271-273 (1984)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE Filing Date		Complete if Known			
-	10 10 10 110 110 110			Application Number	10/518,128
INF	ORMATION	I DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	NFORMATION DISCLOSUSTATEMENT BY APPLICA (Use as many sheets as necessary)	occessed	Art Unit	1646	
	(Use as many sne	ets as n	ecessary	Examiner Name	LI, RUIXIANG
Sheet	10	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Corp, E.S., et al., Peptides 22, 493-499 (2001)	
		Corp, E.S., et al., Am J Physiol 259, R317-R323 (1990)	
		Coruzzi, G., et al., Arch Int Pharmacodyn Ther 302, 232-241 (1989)	
		Cotton, R.G. Mutat Res 285, 125-144 (1993)	
		Cotton, R.G., et al., Proc Natl Acad Sci U S A 85, 4397-4401 (1988)	
		Cox, H.M. et al., Br J Pharmacol 101, 247-252 (1990)	
		Cox, H.M., et al., J Physiol 398, 65-80 (1988)	
		Cox, H.M., et al., Regul Pept 75-76, 3-8 (1998)	
		Dea, D., et al., Gastroenterology 96, 695-703 (1989)	
		Deng, X., et al. Dig Dis Sci 46, 156-165 (2001)	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO		t or 1995, no persons at	Complete if Known		
				Application Number	10/518,128	
			CLOSURE	Filing Date	June 13, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Bronislava Gedulin	
	(Use as many she	ets as n	ecessary)	Art Unit	1646	
	(GGG as many sno	0.0 00 11		Examiner Name	LI, RUIXIANG	
Sheet	11	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Dox, I.G., et al., Definition of 'islet'. In: Anonymous The HarperCollins Illustrated Medical Dictionary, 1st edn. pp. 227 New York: HarperCollins Publishers, Inc.] (1993)	
		Dumont, Y., et al., Eur J Pharmacol 238, 37-45 (1993)	
		Dumont Y, et al., Society for Neuroscience Abstracts. 1993;19:726. Abstract 299.8.	
		Eberlein, G.A., et al., Peptides 10, 797-803 (1989)	
		Ebert, R. Z Gastroenterol Verh 23, 165-170 (1988)	
		Eto, B., et al., Peptides 16, 1403-1409 (1995)	
		Fackelmann USA Today, Health and Science Gut hormone could curb urge to overeat. (Aug 7 2002)	
		Feinstein, R.D., et al., J Med Chem 35, 2836-2843 (1992)	
		Ferber, S., et al., Journal of Biological Chemistry 269, 11523-11529 (1994)	
		Fournier, A., et al., Mol Pharmacol 45, 93-101 (1994)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMBERCE

	itute for form 1449/PTO FORMATION DISCLOSUR ATEMENT BY APPLICAN (Use as many sheets as necessary)		Complete if Known		
				Application Number	10/518,128
				Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	ets as n	ecessary)	Art Unit	1646
				Examiner Name	LI, RUIXIANG
Sheet	12	of	31	Attorney Docket Number	0402-UTL-5

	T	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Freshney, R.I. (Ed.) Culture of Animal Cells: A Manual of Basic Technique, pp. 4 New York: Alan R. Liss, Inc] (1983)	
		Garlicki, J., et al., Am J Physiol 258, E40-E4 (1990)	
		Gedulin, B., et al., Gastroenterology 108, A604 (1995)	
		Gehlert, D.R. Proc Soc Exp Biol Med 218, 7-22 (1998)	
	-	Gibbs, R.A., et al., Nucleic Acids Res 17, 2437-2448 (1989)	
		Gobbi, M., et al., J Neurochem 72, 1663-1670 (1999)	
		Gold, G., et al., Diabetes 30, 77-82 (1981)	
		Gomez, G., et al., Am J Physiol 268, G71-G81 (1995)	
		Goodlad RA, et al., Digestion. 46 Suppl 2:177-181 1990	
		Gordon, E.A., et al., Neurosci Lett 119, 187-190 (1990)	

Examiner	 Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO				Complete if Known
				Application Number	10/518,128
INF	ORMATION	I DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	note ae n	accessari	Art Unit	1646
	(Ose as many sne	:e ts as 11	ecessary)	Examiner Name	LI, RUIXIANG
Sheet	13	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Grandt, D., et al., Regul Pept 51, 151-159 (1994)	
		Grandt, D., et al., Biochem Biophys Res Commun 186, 1299-1306 (1992)	
		Greeley, G.H. Jr, et al., Proc Soc Exp Biol Med 189, 325-328 (1988)	
		Greeley, G.H. Jr, et al., Am J Physiol 254, E513-E517 (1988)	
		Grieco P, et al., Tetrahedron Lett.43:6297-6299 (2002)	
		Groth, C.G., et al., Transplant Proc 24, 972-973 (1992)	
		Grouzmann, E., et al., Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 519B (1993)	
		Grundemar, L., et al., Regul Pept 62, 131-136 (1996)	
		Gu X, et al., Tetrahedron Lett. 44:5863-5866 (2003)	
		Guan, D., et al., Endocrinology 128, 911-916 (1991)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO				Complete if Known
Cabalita	10.10.10.111.174.10.170			Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	ote ae n	eressan/l	Art Unit	1646
	(USC US MUNY SHE	013 43 77		Examiner Name	LI, RUIXIANG
Sheet	14	of	31	Attorney Docket Number	0402-UTL-5

. <u> </u>	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Gue, M., et al., Br J Pharmacol 118, 237-242 (1996)	
		Gustavsson, S., et al., Scand J Gastroenterol 12, 993-997 (1977)	
		Hagan, M.M. et al., Pharmacol Biochem Behav 45, 941-944 (1993)	
		Halaas, J.L., et al., Science 269, 543-546 (1995)	
		Halatchev, I.G., et al., Endocrinology 145, 2585-2590 (2004)	
		Hanessian S, et al., Tetrahedron 53:12789-12854 (1997)	
		Harding, R.K. et al., Peptides 10, 21-24 (1989)	
		Haynes, J.M., et al., Br J Pharmacol 122, 1530-1536 (1997)	
		Henry, M., et al., Obes Res 13, 36-47 (2005)	
		Hoentjen, F., et al., Scand J Gastroenterol 35, 166-171 (2000)	
			L

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	te for form 1449/PTO				Complete if Known
Cubuma				Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	STATEMENT BY APPLICAN			First Named Inventor	Bronislava Gedulin
	(Use as many she	ote se n	ecessary)	Art Unit	1646
	lose as many sne	C 63 11	acessary)	Examiner Name	LI, RUIXIANG
Sheet	15	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Holliday, N.D. et al., Br J Pharmacol 119, 321-329 (1996)	
		Hsu, I.C., et al., Carcinogenesis 15, 1657-1662 (1994)	
		Hu, Y., et al., J Biol Chem 271, 26315-26319 (1996)	
		Hughes, S.D., et al., Proceedings of the National Academy of Sciences of the United States of America 89, 688-692 (1992)	
		Inui, A. Trends Pharmacol Sci 20, 43-46 (1999)	
		Iyengar, S., et al., J Pharmacol Exp Ther 289, 1031-1040 (1999)	
		Jackerott, M. et al., Endocrinology 138, 5013-5018 (1997)	
		Jackerott, M., et al., J Histochem Cytochem 44, 809-817 (1996)	
		Johnson, J.H., et al., Science 250, 546-549 (1990)	
		Jones, P.M. et al., Endocr Rev 19, 429-461 (1998)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	IFORMATION DISCLOSUR TATEMENT BY APPLICAN (Use as many sheets as necessary)		Complete if Known		
Coodina				Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(llea se many cha	ate se r	nacassan/l	Art Unit	1646
	(Ose as many sne	013 43 7	·	Examiner Name	LI, RUIXIANG
Sheet	16	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kanatani, A., et al., Biochem Biophys Res Commun 272, 169-173 (2000)	
		Kanatani, A., et al., Biochem Biophys Res Commun 266, 88-91 (1999)	
		Kanatani, A., et al., Endocrinology 141, 1011-1016 (2000)	
		Karlsson S, et al., Acta Physiol Scand.157:305-306 (1996)	
		Kato, K., et al., Peptides 16, 1257-1262 (1995)	
		Kawakubo, K., et al., Brain Res 854, 30-34 (2000)	
		Keire, D.A., et al., Peptides 23, 305-321 (2002)	
		Keire, D.A., et al., Biochemistry 39, 9935-9942 (2000)	
		Keire, D.A., et al., Am J Physiol 279, G126-G131 (2000)	
		Kimmel, J.R., et al., Endocrinology 83, 1323-1330 (1968)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ite for form 1449/PTC				Complete if Known	1
				Application Number	10/518,128	
INF	ORMATIO	N DIS	CLOSURE	Filing Date	June 13, 2003	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin	
	(Use as many s	hoote as e	2000000001	Art Unit	1646	
	(Use as many s	neets as r	iecessary)	Examiner Name	LI, RUIXIANG	
Sheet	17	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kirby, D.A., et al., J Med Chem 36, 3802-3808 (1993)	
		Kirby, D.A., et al., J Med Chem 38, 4579-4586 (1995)	
		Kopelman, P.G. Nature 404, 635-643 (2000)	
		Korsgren, O., et al., Transplantation 45, 509-514 (1988)	
		Krasinski, S.D., et al., Mol Endocrinol 5, 433-440 (1991)	
		Krstenansky, J.L., et al., Proc Natl Acad Sci U S A 86, 4377-4381 (1989)	
		Krstenansky, J.L., et al., Neuropeptides 17, 117-120 (1990)	
		Kruger, D.F., et al., Diabetes Educ 25, 389-397; quiz 398 (1999)	
		Kumagai Braesch, M., et al., Transplant Proc 24, 679-680 (1992)	
		Kushi, A., et al., Proc Natl Acad Sci U S A 95, 15659-15664 (1998)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO		· · · · · · · · · · · · · · · · · · ·		Complete if Known
Cooma				Application Number	10/518,128
INFO	DRMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	ate ae n	ecessary)	Art Unit	1646
	(OSC US Mully SHC		occssary	Examiner Name	LI, RUIXIANG
Sheet	18	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Lacy, P.E., et al., Science 254, 1782-1784 (1991)	
		Landegren, U., et al., Science 241, 1077-1080 (1988)	
		Leban, J.J., et al., J Med Chem 38, 1150-1157 (1995)	
		Leibowitz, S.F. et al., Peptides 12, 1251-1260 (1991)	
		Liu, C.D., et al., J Gastrointest Surg 5, 147-152 (2001)	
		Liu, X.M., et al., Diabetes 40, 858-66 (1991)	
		Lloyd, K.C.K., et al., Am J Physiol 270, G123-G127 (1996)	
		Lluis, F., et al., Gastroenterology 94, 137-144 (1988)	
		Lundberg, J.M., et al., Proc Natl Acad Sci U S A 79, 4471-4475 (1982)	
		Lundell, I., et al., J Biol Chem 270, 29123-29128 (1995)	

Examiner	Date	,
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO**: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known			
Cubband				Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(lica ac many cha	ate ae n	arassan/)	Art Unit	1646
	(USE as many sine	ets as 11	ecessary)	Examiner Name	LI, RUIXIANG
Sheet	19	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Lyznicki JM, et al., Am Fam Physician. 63:2185-2196 (2001)	
		Makimura, H. et al., Obesity Poster Abstract No. 118 "Adrenalectomy stimulated hypothalamic proopiomelanocortin mRNA but does not correct obesity in diet-induced obese mice."	
		Malaisse-Lagae, F., et al., Experientia 33, 915-917 (1977)	
		Markison S., et al., Obesity Poster Abstract No. 119 "Selective melanin-concentrating hormone receptor antagonists decrease feeding in rodents."	
ï		Marsh, D.J., et al., Nat Med 4, 718-721 (1998)	
		Martin, J.R. Brain Res 1002, 11-20 (2004)	
		Martin, N.M., et al., Int J Obes Relat Metab Disord 28, 886-893 (2004)	
		Mashiko, S., et al., Endocrinology 144, 1793-1801 (2003)	
		Mashiko et al., Obesity Poster Abstract No. 120 "Characterization of neuropeptide Y Y5 receptor mediated obesity in mice."	
		Maxam, A.M. et al., Proc Natl Acad Sci U S A 74, 560-564 (1977)	

Examiner		Date			
Signature		Conside	ered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
as collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO				Complete if Known
				Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	ets as n	ecessary)	Art Unit	1646
	(030 as many sne	.013 43 77	eucessury,	Examiner Name	LI, RUIXIANG
Sheet	20	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Mazelin L, et al., J Auton Nerv Syst.73:38-45 (1998)	
		Medeiros, M.D. et al., Endocrinology 134, 2088-2094 (1994)	
		Michel, M.C., et al., Pharmacol Rev 50, 143-150 (1998)	
		Morley, J.E. Neuropsychobiology 21, 22-30 (1989)	
		Morley, J.E. et al., Life Sci 41, 2157-2165 (1987)	
		Morley, J.E., et al., Am J Physiol 267, R178-R184 (1994)	
		Morley, J.E., et al., Brain Res 341, 200-203 (1985)	
		Morris GP, et al., Gastroenterology 96:795-803 (1989)	
		Mulder, H., et al., Microscopy Research and Technique 43, 313-321 (1998)	
		Mullins, D., et al., Mol Pharmacol 60, 534-540 (2001)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB control number.

	Ubstitute for form 1449/PTO NFORMATION DISCLOSURE STATEMENT BY APPLICAN			Complete if Known	
Oubstitu	10 10/10/11/ 1440/1 10			Application Number	10/518,128
INF	DRMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	ate ae n	ocacean)	Art Unit	1646
	(OSB as many sne		ecessary)	Examiner Name	LI, RUIXIANG
Sheet	21	of	31	Attorney Docket Number	0402-UTL-5

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	1
Examiner Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Munson, P.J. et al., Anal Biochem 107, 220-239 (1980)	
		Murakami, Y., et al., J Med Chem 42, 2621-2632 (1999)	
		Murase, S., et al., J Biochem (Tokyo) 119, 37-41 (1996)	
		Myers, R.M., et al., Science 230, 1242-1246 (1985)	
		Myers, R.M., et al., Nature 313, 495-498 (1985)	
		Naeve, C.W., et al., Biotechniques 19, 448-453 (1995)	
		Nakajima, M., et al., J Pharmacol Exp Ther 268, 1010-1014 (1994)	
		Nakazawa, H., et al., Proc Natl Acad Sci U S A 91, 360-364 (1994)	
		Naslund, E., et al., Int J Obes Relat Metab Disord 23, 304-311 (1999)	
		Ngo, J.T., et al., The protein folding problem and tertiary structure prediction, pp. 491-495. Boston: Birkhauser (1994)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO NFORMATION DISCLOSURE STATEMENT BY APPLICAN		Complete if Known			
Cubuma				Application Number	10/518,128	
				Filing Date	June 13, 2003	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin	
	(Use as many she	ets as n	ecessary)	Art Unit	1646	
	(030 us many sno			Examiner Name	LI, RUIXIANG	
Sheet	22	of	31	Attorney Docket Number	0402-UTL-5	

			
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Nieuwenhuizen, A.G., et al., Diabetologia 37, 871-878 (1994)	
		Nightingale, J.M., et al., Gut 39, 267-272 (1996)	
		Odagiri, H., et al., J Biol Chem 271, 1909-1915 (1996)	
		Okada, S., et al., Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 520B (1993)	
		Okumura, T., et al., Neuroscience Letters 178, 167-170 (1994)	
		Orita, M., et al., Proc Natl Acad Sci U S A 86, 2766-2770 (1989)	
		Otonkoski, T., et al., Diabetes 37, 286-291 (1988)	
		Pappas, T.N., et al., Gastroenterology 91, 1386-1389 (1986)	
		Pappas, T.N., et al., Am J Physiol 248, G118-G123 (1985)	
		Parker, E.M., et al., Eur J Pharmacol 349, 97-105 (1998)	
			\blacksquare

Examiner	 Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO INFORMATION STATEMENT I				Complete if Known
Substitu	te 101 101111 1443/F10			Application Number	10/518,128
INF	ORMATION	I DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(llee ee menu eh			Art Unit	1646
	(Use as many sh	eets as n	ecessary)	Examiner Name	LI, RUIXIANG
Sheet	23	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Parker, E.M., et al., Peptides 21, 393-399 (2000)	
		Parker, S.L. et al., Can J Physiol Pharmacol 78, 150-161 (2000)	
		Pelleymounter, M.A., et al., Science 269, 540-543 (1995)	
		Pheng, L.H., et al., Br J Pharmacol 139, 695-704 (2003)	
·		Pironi, L., et al., Gastroenterology 105, 733-739 (1993)	t
		Pi-Sunyer, F.X. Obes Surg 12 Suppl 1, 6S-11S (2002)	
		Pokrovsky, V.I. Nephrotomy: renal insufficiency. In: Academician of RAMS, (Ed.) Small Medical Encyclopedia, pp. 59-62. Moscow: Meditisina Publishers] (1996) - English tra	
		Potter, E.K., et al., Eur J Pharmacol 267, 253-262 (1994)	
		Randle, P.J. Diabetes Metab Rev 14, 263-283 (1998)	
		Renshaw, D. et al., Curr Drug Targets 6, 171-179 (2005)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ubstitute for form 1449/PTO				Complete if Known
				Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	ote se n	ecossan)	Art Unit	1646
	(OSC BS Many SNC		uccssury,	Examiner Name	LI, RUIXIANG
Sheet	24	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Rhodes, C.J. et al., J Cell Biol 105, 145-153 (1987)	
		Rico, L. et al., Obesity Poster Abstract No. 117 "Early and dissociated leptin and insulin resistance in transgenic mice overexpressing leptin from keratinocytes."	
		Rissanen, A., et al., BMJ 301, 835-837 (1990)	
		Rist, B., et al., Eur J Biochem 247, 1019-1028 (1997)	
		Rist, B., et al., FEBS Lett 394, 169-173 (1996)	
		Robbins, L.S., et al., Pathologic Basis of Disease, 3rd edn. pp. 972-990. Philadelphi: W. B. Saunders Company] (1984)	
		Saiki, R.K., et al., Nature 324, 163-166 (1986)	
		Saiki, R.K., et al., Proc Natl Acad Sci U S A 86, 6230-6234 (1989)	
		Sainsbury, A., et al., Genes Dev 16, 1077-1088 (2002)	
	!	Saleeba, J.A. et al., Methods Enzymol 217, 286-295 (1993)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/518,128	
INFORMATION DISCLOSURE	Filing Date	June 13, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Bronislava Gedulin	
(Use as many sheets as necessary)	Art Unit	1646	
(Use as many sneets as necessary)	Examiner Name	LI, RUIXIANG	
Sheet 25 of 31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Sandberg M, et al., J Med Chem.41:2481-2491 (1998)	
		Sander, M., et al., Proc Natl Acad Sci U S A 95, 11572-11577 (1998)	
		Sanger, F., et al., Proc Natl Acad Sci U S A 74, 5463-5467 (1977)	
		Sato, N., et al., J Med Chem 46, 666-669 (2003)	
		Savage, A.P., et al., Gut 28, 166-170 (1987)	
		Scatchard, G., Ann NY Acad Sci 51, 660 (1949)	
		Scheen, A.J. Drugs 54, 355-368 (1997)	
		Schmidt PT, et al., Eur J Gastroenterol Hepatol 17:207-212 (2005)	
,	:	Schuit, F.C. Horm Res 46, 99-106 (1996)	
		Schwartz, M.W., et al., Nature 404, 661-671 (2000)	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO INFORMATION DISCLOSUR			Complete if Known	
				Application Number	10/518,128
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin
	(Use as many she	ote ac r	oocassan/l	Art Unit	1646
	(US e as many sne	ets as 1	iecessary)	Examiner Name	LI, RUIXIANG
Sheet	26	of	31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Servin, A.L., et al., Endocrinology 124, 692-700 (1989)	
		Shan, L., et al., Science 297, 2275-2279 (2002)	
		Sheikh, S.P. Am J Physiol 261, G701-G715 (1991)	
		Silva, A.P., et al., Clin Chim Acta 326, 3-25 (2002)	
		Simeonovic, C.J. et al., Aust J Exp Biol Med Sci 60 Pt 4, 383-390 (1982)	
		Slack, J.M. Development 121, 1569-1580 (1995)	
		Small, C.J., et al., Proc Natl Acad Sci U S A 94, 11686-11691 (1997)	
		Soll, R.M., et al., Eur J Biochem 268, 2828-2837 (2001)	
		Souers AJ, et al., Tetrahedron 57:7431-7448 (2001)	
		Stanley, B.G., et al., Peptides 6, 1205-1211 (1985)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO		or tood, no percome an	Complete if Known			
Oubstitu				Application Number	10/518,128		
INF	ORMATION	DIS	CLOSURE	Filing Date	June 13, 2003		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Bronislava Gedulin		
	(Use as many she			Art Unit	1646		
	(Use as many sne	ets as n	ecessary)	Examiner Name	LI, RUIXIANG		
Sheet	27	of	31	Attorney Docket Number	0402-UTL-5		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		St-Onge, M.P. et al., J Nutr 132, 329-332 (2002)	
		Sullivan, S.J., et al., Science 252, 718-721 (1991)	
		Surwit, R.S., et al., Metabolism - Clinical and Experimental 44, 645-651 (1995)	
		Suzuki, T., et al., Gastroenterology 85, 114-121 (1983)	
		Taniguchi, H., et al., Eur J Pharmacol 312, 227-233 (1996)	
		Tatemoto, K. Proc Natl Acad Sci U S A 79, 2514-2518 (1982)	
		Tatemoto, K. Proc Natl Acad Sci U S A 79, 5485-5489 (1982)	
		Tatemoto, K., et al., Nature 296, 659-660 (1982)	
		Tatemoto, K., et al., Proc Natl Acad Sci U S A 89, 1174-1178 (1992)	
		Tatemoto, K., et al., Biochem Biophys Res Commun 157, 713-717 (1988)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		Complete if Known
- Cabanda 15/15/11/14/5/11/10	Application Number	10/518,128
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Application Number 10/518,128 Filing Date June 13, 2003 First Named Inventor Bronislava Gedulin Art Unit 1646 Examiner Name LI, RUIXIANG	June 13, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Bronislava Gedulin
(Usa as many shoots as nacassan)	Art Unit	1646
(Ose as many sincers as necessary)	Examiner Name	LI, RUIXIANG
Sheet 28 of 31	Attorney Docket Number	0402-UTL-5

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Taylor, I.L. J Dairy Sci 76, 2094-2101(1993)	
		Taylor, I.L. et al., Am J Physiol 248, G277-G280 (1985)	
		Teyssen, S., et al., Pancreas 13, 80-88 (1996)	
		Thorens, B., et al., Proceedings of the National Academy of Sciences of the United States of America 87, 6492-6496 (1990)	,
		Thum, A., et al., Exp Clin Endocrinol Diabetes 110, 113-118 (2002)	
		Tito JM, et al., Am J Surg.165:690-696 (1993)	
		Totheroh, G., "Science Offers Promising Treatment for an Overweight Nation" CBN News (Sept 4, 2003)	
		Tsai JH, et al., Bioorg Med Chem 7:29-38 (1999)	
		Tschop, M., et al., Nature 430, 1 p following 165; discussion 2 p following 165 (2004)	
		Tseng, W.W. et al., Peptides 23, 389-395 (2002)	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO	Complete if Known		
Cassillate is is in 14451 10	Application Number	10/518,128	
INFORMATION DISCLOSURE	Filing Date	June 13, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Bronislava Gedulin	
(Use as many sheets as necessary)	Art Unit	1646	
(ose as many sneets as necessary)	Examiner Name	LI, RUIXIANG	
Sheet 29 of 31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Tuch, B.E., et al., J Endocrinol 132, 159-167 (1992)	
		Turnbull, A.V., et al., Diabetes 51, 2441-2449 (2002)	
		Ueno, N., et al., Gastroenterology 117, 1427-1432 (1999)	
		Upchurch, B.H., et al., Development 120, 245-252 (1994)	
		Valera, A., et al., J Biol Chem 269, 28543-28546 (1994)	
		Valet, P., et al., J Clin Invest 85, 291-295 (1990)	
		van Santbrink, E.J. et al., J Clin Endocrinol Metab 82, 3597-602 (1997)	
		Verchere, C.B., et al, Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 517B., (1993)	
		Virgilio AA, et al., Tetrahedron 53:6635-6644 (1997)	
		Voisin, T., et al., J Biol Chem 268, 20547-20554 (1993)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ite for form 1449/PTO			Complete if Known		
Gubanto	10 101 101111 14401 10			Application Number	10/518,128	
INF	(Use as many sheets as necessary)	CLOSURE	Filing Date	June 13, 2003		
STA	STATEMENT BY APPLICANT		First Named Inventor	Bronislava Gedulin		
	/lloo oo many sha	ata aa n		Art Unit	1646	
	(Ose as many sne	ets as 11	ecessary)	Examiner Name	LI, RUIXIANG	
Sheet	30	of	31	Attorney Docket Number	0402-UTL-5	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Wager-Page, S.A., et al., Can J Physiol Pharmacol 71, 768-775 (1993)	
-		Wahoff, D.C., et al., Transplant Proc 26, 804 (1994)	
		Walker, M.W., et al., J Neurosci 8, 2438-2446 (1988)	
		Walker, M.W., et al., Peptides 18, 609-612 (1997)	
1 10		Wang, Z.L., et al., Endocrine Society Program & Abstracts 75th Annual Meeting, Las Vegas, NV, June 9-12 180. Abstract 518B (1993)	
		Weinberg, D.H., et al., J Biol Chem 271, 16435-16438 (1996)	
		Wells, J.A. Biochemistry 29, 8509-8517 (1990)	
		Widdowson, P.S., et al., Brain Res 778, 242-250 (1997)	
		Wilding, J.P. Diabet Med 19, 619-627 (2002)	
		Wiley, J.W., et al., Gastroenterology 100, 865-872 (1991)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known		
- Substitute 181 18111 14431 16	Application Number	10/518,128		
INFORMATION DISCLOSUR	E Filing Date	June 13, 2003		
STATEMENT BY APPLICAN	First Named Inventor	Bronislava Gedulin		
(House many choose as page card	Application Number 10/518,128 MATION DISCLOSURE Filing Date June 13, 2003 First Named Inventor Bronislava Gedulin Art Unit 1646			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Application Number 10/518,128 June 13, 2003 Bronislava Gedulin Art Unit 1646 Examiner Name LI, RUIXIANG				
Sheet 31 of 31	Attorney Docket Number	0402-UTL-5		

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Wilson, J.D., et al., Diabetes 38 Suppl 1, 217-219 (1989)	
		Wimalawansa, S.J. Crit Rev Neurobiol 11, 167-239 (1997)	
		Yang, H., et al., Br J Pharmacol 123, 1549-1554 (1998)	
		Yang, H. et al., Am J Physiol 268, G943-G948 (1995)	
		Yoshinaga, K., et al. Am J Physiol 263, G695-G701 (1992)	
		Young, A.A. et al., Program and Abstracts, 10th International Congress of Endocrinology 419 (poster P2-58) (1996)	
		Young, A.A., et al., Metabolism 45, 1-3 (1996)	
		Zai, H., et al., Regul Pept 61, 181-188 (1996)	
, ,		HYPERDICTIONARY – definition of "Structure Activity Relationship"	
		On-Line Medical Dictionary. Dept. of Oncology, University of Newcastle upon tyne. The Cancerweb Project Copyright 1997-2004 (definitions of "hyperlipoproteinaemia"; "hyperlip	

Examiner	· · · · · · · · · · · · · · · · · · ·	Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.